Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2014

View Archived Issues

[123I]ABC-577 as a novel Abeta SPECT imaging agent

Inhibiting tau oligomer formation for the potential treatment of AD

Johnson & Johnson reviews progress of second quarter 2014

Navidea forms radiopharmaceuticals enterprise with Rheumco

Amgen reports first phase III trial results for AMG-416 in secondary hyperparathyroidism

Rigel advances fostamatinib into phase III for ITP

ViaCyte files IND for VC-01 encapsulated cell replacement therapy for type 1 diabetes

Bayer reports 2-year results from VIVID-DME study of aflibercept

ITCA-650 proves beneficial in patients with diabetes and severe hyperglycemia

Combined acetylcholinesterase inhibitor/calcium channel blocker tested in AD model

Novel transgenic model of early Alzheimer's disease induces amyloid cascade

Sanwa Kagaku Kenkyusho discloses new V2 receptor agonists

Novel agents for Alzheimer's disease disclosed by JST

Purdue Pharma divulges novel opioid receptor agonists

Durata Therapeutics launches Dalvance in U.S.

Cadila Healthcare patents novel HIF prolyl-hydroxylase inhibitors

Phase I study of Alkermes' MS candidate ALKS-8700 begins

Polish scientists prepare novel peptidomimetics

Basilea Pharmaceutica synthesizes novel PDE4 inhibitors

Rexahn advances phase I study of Supinoxin for solid tumors

Chugai gains rights to market palonosetron-based products in U.K. and Ireland

AbbVie and Shire reach agreement on business combination

MedPacto advances preparations for first phase I study of TEW-7197

Auspex Pharmaceuticals initiates pivotal trial of SD-809 in tardive dyskinesia

Basilea updates on European launch strategy for ceftobiprole medocaril

Bioniche plans BLA submission for bladder cancer therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...